Nestlé Health Science has announced it has entered into a strategic collaboration with DBV Technologies to develop and bring to market a patch-test tool, MAG1C, for the diagnosis of Cow’s Milk Protein Allergy (CMPA) in infants.
CMPA impacts up to 2-3% of infants and young children, and Nestlé says that it is difficult to diagnose.French company DBV’s patch-test will enable early and accurate diagnosis of the condition, leading to early nutritional intervention, which Nestlé says is a strong fit with its Althéra, Alfaré and Alfamino products for babies and children with food allergies and intolerances.Upfront payment for developmentUnder the terms of the agreement, DBV will be eligible to receive up to €100m ($111.4m) in development, registration and commercial milestones, including an upfront payment of €10m ($11.1m).
DBV will pay all development-related costs of MAG1C, including a worldwide clinical program, as well as manufacturing costs. If MAG1C is successfully manufactured, the company will receive a supply price with a mark-up from Nestlé Health Science.In addition, Nestlé Health Science will pay DBV tiered royalties on global product sales.
Looking for 2021 approvalGreg Behar, CEO of Nestlé Health Science, said that the tool can become a breakthrough diagnostic for CMPA.“Early diagnosis and nutritional intervention helps get infants hap…